Short Interest in Bone Biologics Co. (NASDAQ:BBLG) Rises By 69.0%

Bone Biologics Co. (NASDAQ:BBLG) saw a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 21,800 shares, a growth of 69.0% from the May 31st total of 12,900 shares. Approximately 4.2% of the company’s stock are short sold. Based on an average daily volume of 79,700 shares, the short-interest ratio is currently 0.3 days.

Bone Biologics Trading Up 1.5 %

NASDAQ:BBLG traded up $0.02 during trading hours on Friday, reaching $1.23. 30,827 shares of the stock were exchanged, compared to its average volume of 100,682. Bone Biologics has a 52 week low of $1.13 and a 52 week high of $14.16. The firm has a 50 day simple moving average of $1.61 and a 200-day simple moving average of $2.59.

Bone Biologics (NASDAQ:BBLG) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($1.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.60) by $6.29. On average, analysts predict that Bone Biologics will post -5.32 EPS for the current year.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.